MedPath
HSA Approval

IPROVENT INHALER 20 mcg/puff

SIN14257P

IPROVENT INHALER 20 mcg/puff

IPROVENT INHALER 20 mcg/puff

October 23, 2012

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

AEROSOL, METERED

RESPIRATORY (INHALATION)

Medical Information

R03BB01

ipratropium bromide

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Laboratorio ALDO-UNIÓN S.L.

Active Ingredients

Ipratropium bromide monohydrate 21 mcg eqv to anhydrous Ipratropium bromide

20 mcg/dose

Ipratropium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

IPROVENT INHALER 20 mcg/puff - HSA Approval | MedPath